S
Shir Hazut Krauthammer
Researcher at Tel Aviv Sourasky Medical Center
Publications - 6
Citations - 152
Shir Hazut Krauthammer is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 4 publications receiving 36 citations.
Papers
More filters
Journal ArticleDOI
Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [ 18 F]FDG PET-CT and relevance to study interpretation.
TL;DR: In this article, the authors identified on [18F]FDG PET-CT studies vaccine-associated hypermetabolic lymphadenopathy (VAHL) in axillary or supraclavicular lymph nodes (ASLN) ipsilateral to the vaccination site.
Journal ArticleDOI
Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
Dan Cohen,Shir Hazut Krauthammer,Yael C Cohen,Yael C Cohen,Chava Perry,Chava Perry,Irit Avivi,Irit Avivi,Yair Herishanu,Yair Herishanu,Einat Even-Sapir,Einat Even-Sapir +11 more
TL;DR: VAHL on [18F]FDG PET-CT of patients with hematologic malignancy may reflect GC B-cell proliferation and an effective humoral response elicited by BNT162b2 vaccine.
Journal ArticleDOI
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
Dan Cohen,Efrat Luttwak,Ofrat Beyar-Katz,Ofrat Beyar-Katz,Shir Hazut Krauthammer,Yael Bar-On,Yael Bar-On,Odelia Amit,Odelia Amit,Ronit Gold,Chava Perry,Chava Perry,Irit Avivi,Irit Avivi,Ron Ram,Ron Ram,Einat Even-Sapir,Einat Even-Sapir +17 more
TL;DR: In this paper, the authors identify the specific parameters that should be addressed when reporting PET-CT studies in the clinical setting of CAR-T therapy, and they use SUVmax, TMTV, and TLG in all scans.
Posted ContentDOI
A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [18F]FDG PET-CT studies performed in oncologic patients.
TL;DR: VAHL is commonly identified on [18F]FDG PET-CT performed within the first 5 days from the third BNT162b2 vaccine doseadministration, and is even less likely in older and obese patients.
Journal ArticleDOI
Beyond Visual Assessment of Basal Ganglia Uptake: Can Automated Method and Pineal Body Uptake Assessment Improve Identification of Nigrostriatal Dysfunction on 18F-DOPA PET/CT?
TL;DR: In this paper , the authors evaluated the diagnostic performance of an automated method that assesses BG uptake (AM-BG) and of methods that assess pineal body uptake, and examined whether these methods can enhance the diagnosis performance of VA-BG alone.